^
BCR-ABL1 fusion
CML
asciminib
Sensitive: B - Late Trials
Novartis Press Release - 2 days - (New B)
No biomarker
CLL
venetoclax + ibrutinib
Sensitive: B - Late Trials
Businesswire - 2 days - (New B)
TP53 wild-type
CLL
venetoclax
Sensitive: A2 - Guideline
NICE - 1 week - (New A2)
TP53 mutation
CLL
venetoclax
Sensitive: A1 - Approval
NICE - 1 week - (New A2)
Chr del(17p)
CLL
venetoclax
Sensitive: A1 - Approval
NICE - 1 week - (New A2)
TP53 mutation
AML
DHODH inhibitor
Sensitive: D – Preclinical
Cancer Res - 1 week - (New D)
No biomarker
AML
KRP-203
Sensitive: B - Late Trials
PRNewswire - 3 weeks - (New B)
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
FLT3 mutation
AML
gilteritinib
Sensitive: A1 - Approval
IDH2 mutation
AML
enasidenib
Sensitive: A1 - Approval
No biomarker
AML
glasdegib
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + ibrutinib
Sensitive: A1 - Approval
No biomarker
AML
azacitidine oral
Sensitive: A1 - Approval
No biomarker
AML
cytarabine / daunorubicin liposomal formulation
Sensitive: A1 - Approval
Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
dasatinib
Sensitive: A1 - Approval
BCR-ABL1 T315I
CML
asciminib
Sensitive: A1 - Approval
No biomarker
CLL
orelabrutinib
Sensitive: A1 - Approval
FLT3 mutation
AML
midostaurin
Sensitive: A1 - Approval
CD33 positive
AML
gemtuzumab ozogamicin
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
imatinib
Sensitive: A1 - Approval
No biomarker
CML
omacetaxine mepesuccinate
Sensitive: A1 - Approval
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
CD20 expression
CLL
rituximab-arrx
Sensitive: A1 - Approval
BCR-ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
BCR-ABL1 T315I
ALL
ponatinib
Sensitive: A1 - Approval
No biomarker
ALL
blinatumomab
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
No biomarker
AML
venetoclax
Sensitive: A1 - Approval
No biomarker
CML
ponatinib
Sensitive: A1 - Approval
No biomarker
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + rituximab
Sensitive: A1 - Approval
No biomarker
CLL
zanubrutinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
ponatinib
Sensitive: A1 - Approval
ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
Chr t(1;16)(q12;q11.2)
CML
ponatinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
dasatinib
Sensitive: A1 - Approval
No biomarker
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
ofatumumab
Sensitive: A1 - Approval
CD19 positive
ALL
blinatumomab
Sensitive: A1 - Approval
No biomarker
AML
decitabine
Sensitive: A1 - Approval
No biomarker
Hairy Cell Leukemia
cladribine
Sensitive: A1 - Approval
Chr t(15;17)
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
PML-RARA fusion
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
CD20 positive
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
rituximab / hyaluronidase
Sensitive: A1 - Approval
No biomarker
CML
busulfan
Sensitive: A1 - Approval
No biomarker
ALL
mercaptopurine
Sensitive: A1 - Approval
No biomarker
AML
azacitidine
Sensitive: A1 - Approval
No biomarker
CMML
azacitidine
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
nilotinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab + acalabrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
acalabrutinib
Sensitive: A1 - Approval
IDH1 mutation
AML
ivosidenib
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
bosutinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
TP53 mutation
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
Chr del(17p)
CLL
acalabrutinib
Sensitive: A1 - Approval
TP53 mutation
CLL
acalabrutinib
Sensitive: A1 - Approval
No biomarker
CLL
alemtuzumab
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
imatinib
Sensitive: A1 - Approval
No biomarker
ALL
vincristine liposomal
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
No biomarker
Hairy Cell Leukemia
moxetumomab pasudotox
Sensitive: A1 - Approval
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
TP53 mutation
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
Chr del(17p)
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
No biomarker
CLL
duvelisib
Sensitive: A1 - Approval
No biomarker
CMML
decitabine / cedazuridine
Sensitive: A1 - Approval
No biomarker
AML
idarubicin hydrochloride
Sensitive: A1 - Approval
CD20 positive
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
BCR-ABL1 mutation
CML
asciminib
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive: A1 - Approval
No biomarker
ALL
recombinant Erwinia asparaginase
Sensitive: A1 - Approval
No biomarker
CLL
bendamustine
Sensitive: A1 - Approval
No biomarker
CLL
bendamustine RTD
Sensitive: A1 - Approval
No biomarker
ALL
pegaspargase
Sensitive: A1 - Approval
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive: A1 - Approval
No biomarker
Juvenile Myelomonocytic Leukemia
azacitidine
Sensitive: A1 - Approval
No biomarker
CLL
PCR
Sensitive: A2 - Guideline
Chr del(17p)
CLL
ofatumumab
Sensitive: A2 - Guideline
No biomarker
CLL
FCR
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline